James Investment Research’s iShares iBonds Dec 2027 Term Corporate ETF IBDS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.36M Sell
56,334
-2,101
-4% -$50.8K 0.14% 147
2026
Q1
$1.42M Sell
58,435
-1,993
-3% -$48.4K 0.16% 134
2025
Q4
$1.47M Buy
60,428
+241
+0.4% +$5.86K 0.16% 123
2025
Q3
$1.46M Sell
60,187
-2,656
-4% -$64.4K 0.16% 125
2025
Q2
$1.53M Sell
62,843
-1,068
-2% -$25.8K 0.18% 119
2025
Q1
$1.55M Buy
63,911
+17,643
+38% +$424K 0.2% 114
2024
Q4
$1.11M Sell
46,268
-110
-0.2% -$2.65K 0.13% 137
2024
Q3
$1.13M Sell
46,378
-3,441
-7% -$82.9K 0.13% 148
2024
Q2
$1.18M Buy
49,819
+38,719
+349% +$916K 0.14% 136
2024
Q1
$264K Buy
+11,100
New +$264K 0.03% 272

Other funds holding IBDS

James Investment Research's IBDS Position: Q2 2026 in Review

James Investment Research reduced its iShares iBonds Dec 2027 Term Corporate ETF (IBDS) stake by 3.6% in Q2 2026, selling an estimated $50.8K and leaving 56,334 shares worth $1.36M. The position accounts for 0.14% of the portfolio, ranked #147.

James Investment Research first reported a position in IBDS in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.55M in Q1 2025. 416 funds tracked by Wall St. Rank hold IBDS as of Q2 2026.

  • James Investment Research held 56,334 shares of iShares iBonds Dec 2027 Term Corporate ETF worth $1.36M as of Q2 2026.
  • James Investment Research sold 2,101 iShares iBonds Dec 2027 Term Corporate ETF shares in Q2 2026, an estimated $50.8K.
  • iShares iBonds Dec 2027 Term Corporate ETF made up 0.14% of James Investment Research's portfolio in Q2 2026, its #147 holding.
  • James Investment Research first reported a position in iShares iBonds Dec 2027 Term Corporate ETF in Q1 2024 and has held it in 10 quarters since.
  • James Investment Research's iShares iBonds Dec 2027 Term Corporate ETF position peaked at $1.55M in Q1 2025.
  • 416 funds tracked by Wall St. Rank held iShares iBonds Dec 2027 Term Corporate ETF as of Q2 2026.

Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.